<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38881905</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>TLR2/4 are novel activating receptors for SARS-CoV-2 spike protein on NK cells.</ArticleTitle><Pagination><StartPage>1368946</StartPage><MedlinePgn>1368946</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1368946</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1368946</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">In early infected or severe coronavirus disease 2019 (COVID-19) patients, circulating NK cells are consistently reduced, despite being highly activated or exhausted. The aim of this paper was to establish whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (SP) may directly trigger NK cells and through which receptor(s).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">SP-stimulated human NK cells have been evaluated for the expression of activation markers, cytokine release, and cytotoxic activity, as well as for gene expression profiles and NF-kB phosphorylation, and they have been silenced with specific small interfering RNAs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">SPs from the Wuhan strain and other variants of concern (VOCs) directly bind and stimulate purified NK cells by increasing activation marker expression, cytokine release, and cytolytic activity, prevalently in the CD56<sup>bright</sup>NK cell subset. VOC-SPs differ in their ability to activate NK cells, G614, and Delta-Plus strains providing the strongest activity in the majority of donors. While VOC-SPs do not trigger ACE2, which is not expressed on NK cells, or other activating receptors, they directly and variably bind to both Toll-like receptor 2 (TLR2) and TLR4. Moreover, SP-driven NK cell functions are inhibited upon masking such receptors or silencing the relative genes. Lastly, VOC-SPs upregulate CD56<sup>dim</sup>NK cell functions in COVID-19 recovered, but not in non-infected, individuals.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">TLR2 and TLR4 are novel activating receptors for SP in NK cells, suggesting a new role of these cells in orchestrating the pathophysiology of SARS-CoV-2 infection. The pathogenic relevance of this finding is highlighted by the fact that free SP providing NK cell activation is frequently detected in a SARS-CoV-2 inflamed environment and in plasma of infected and long-COVID-19 subjects.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Landolina, Ricci, Veneziani, Alicata, Mariotti, Pelosi, Quatrini, Mortari, Carsetti, Vacca, Tumino, Azzarone, Moretta and Maggi.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Landolina</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Tumor Immunology Unit, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ricci</LastName><ForeName>Biancamaria</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tumor Immunology Unit, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Veneziani</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Tumor Immunology Unit, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alicata</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Tumor Immunology Unit, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariotti</LastName><ForeName>Francesca Romana</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Tumor Immunology Unit, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelosi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tumor Immunology Unit, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quatrini</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Innate Lymphoid Cells Unit, Immunology Research Area, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortari</LastName><ForeName>Eva Piano</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>B cell Unit, Immunology Research Area, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carsetti</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>B cell Unit, Immunology Research Area, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vacca</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Innate Lymphoid Cells Unit, Immunology Research Area, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tumino</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Innate Lymphoid Cells Unit, Immunology Research Area, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azzarone</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tumor Immunology Unit, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moretta</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Tumor Immunology Unit, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maggi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Tumor Immunology Unit, Bambino Ges&#xf9; Children's Hospital, IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495342">TLR2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495345">TLR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="Y">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051195" MajorTopicYN="Y">Toll-Like Receptor 2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="Y">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NK-cell</Keyword><Keyword MajorTopicYN="N">SARS-CoV2</Keyword><Keyword MajorTopicYN="N">TLRs</Keyword><Keyword MajorTopicYN="N">spike glycoprotein</Keyword><Keyword MajorTopicYN="N">variants of concerns</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>17</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>17</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38881905</ArticleId><ArticleId IdType="pmc">PMC11176535</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1368946</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di Vito C, Calcaterra F, Coianiz N, Terzoli S, Voza A, Mikulak J, et al. . Natural killer cells in SARS-coV-2 infection: pathophysiology and therapeutic implications. Front Immunol. (2022) 13:888248. doi:&#xa0;10.3389/fimmu.2022.888248</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.888248</ArticleId><ArticleId IdType="pmc">PMC9279859</ArticleId><ArticleId IdType="pubmed">35844604</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman M, Faridi RM, Sligl W, Shabani-Rad MT, Dharmani-Khan P, Parker A, et al. . Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Adv. (2020) 4:5035&#x2013;9. doi:&#xa0;10.1182/bloodadvances.2020002650</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020002650</ArticleId><ArticleId IdType="pmc">PMC7594380</ArticleId><ArticleId IdType="pubmed">33075136</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. . Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. (2020) 27:992&#x2013;1000 e3. doi:&#xa0;10.1016/j.chom.2020.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. . Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. (2020) 17:533&#x2013;5. doi:&#xa0;10.1038/s41423-020-0402-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0402-2</ArticleId><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, et al. . Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. (2020) 5:eabd6832. doi:&#xa0;10.1126/sciimmunol.abd6832</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd6832</ArticleId><ArticleId IdType="pmc">PMC7665314</ArticleId><ArticleId IdType="pubmed">32826343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Hou H, Yao Y, Wu S, Huang M, Ran X, et al. . Systemically comparing host immunity between survived and deceased COVID-19 patients. Cell Mol Immunol. (2020) 17:875&#x2013;7. doi:&#xa0;10.1038/s41423-020-0483-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0483-y</ArticleId><ArticleId IdType="pmc">PMC7295144</ArticleId><ArticleId IdType="pubmed">32541836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martinez-Colon GJ, McKechnie JL, et al. . A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. (2020) 26:1070&#x2013;6. doi:&#xa0;10.1038/s41591-020-0944-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0944-y</ArticleId><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. . Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. (2001) 19:197&#x2013;223. doi:&#xa0;10.1146/annurev.immunol.19.1.197</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.19.1.197</ArticleId><ArticleId IdType="pubmed">11244035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, et al. . The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol. (2004) 172:1455&#x2013;62. doi:&#xa0;10.4049/jimmunol.172.3.1455</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.3.1455</ArticleId><ArticleId IdType="pubmed">14734722</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, et al. . Untimely TGFbeta responses in COVID-19 limit antiviral functions of NK cells. Nature. (2021) 600:295&#x2013;301. doi:&#xa0;10.1038/s41586-021-04142-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04142-6</ArticleId><ArticleId IdType="pubmed">34695836</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G, Qi F, Li H, Yang Q, Wang H, Wang X, et al. . The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discovery. (2020) 6:73. doi:&#xa0;10.1038/s41421-020-00225-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-00225-2</ArticleId><ArticleId IdType="pmc">PMC7574992</ArticleId><ArticleId IdType="pubmed">33101705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-Garcia R, et al. . Early IFN-alpha signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. (2021) 54:2650&#x2013;69 e14. doi: 10.1016/j.immuni.2021.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.002</ArticleId><ArticleId IdType="pmc">PMC8416549</ArticleId><ArticleId IdType="pubmed">34592166</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. (2020) 20:269&#x2013;70. doi:&#xa0;10.1038/s41577-020-0308-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId><ArticleId IdType="pmc">PMC7143200</ArticleId><ArticleId IdType="pubmed">32273594</ArticleId></ArticleIdList></Reference><Reference><Citation>Demaria O, Carvelli J, Batista L, Thibult ML, Morel A, Andre P, et al. . Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19. Cell Mol Immunol. (2020) 17:995&#x2013;7. doi:&#xa0;10.1038/s41423-020-0493-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0493-9</ArticleId><ArticleId IdType="pmc">PMC7327215</ArticleId><ArticleId IdType="pubmed">32612152</ArticleId></ArticleIdList></Reference><Reference><Citation>Varchetta S, Mele D, Oliviero B, Mantovani S, Ludovisi S, Cerino A, et al. . Unique immunological profile in patients with COVID-19. Cell Mol Immunol. (2021) 18:604&#x2013;12. doi:&#xa0;10.1038/s41423-020-00557-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00557-9</ArticleId><ArticleId IdType="pmc">PMC7557230</ArticleId><ArticleId IdType="pubmed">33060840</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo-Zapata J, Maldonado-Bernal C. Natural killer cell exhaustion in SARS-CoV-2 infection. Innate Immun. (2022) 28:189&#x2013;98. doi:&#xa0;10.1177/17534259221077750</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17534259221077750</ArticleId><ArticleId IdType="pmc">PMC9389049</ArticleId><ArticleId IdType="pubmed">35733383</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellavite P, Ferraresi A, Isidoro C. Immune response and molecular mechanisms of cardiovascular adverse effects of spike proteins from SARS-coV-2 and mRNA vaccines. Biomedicines. (2023) 11:451. doi:&#xa0;10.3390/biomedicines11020451</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11020451</ArticleId><ArticleId IdType="pmc">PMC9953067</ArticleId><ArticleId IdType="pubmed">36830987</ArticleId></ArticleIdList></Reference><Reference><Citation>Castruita JAS, Schneider UV, Mollerup S, Leineweber TD, Weis N, Bukh J, et al. . SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination. APMIS. (2023) 131:128&#x2013;32. doi:&#xa0;10.1111/apm.13294</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apm.13294</ArticleId><ArticleId IdType="pmc">PMC10107710</ArticleId><ArticleId IdType="pubmed">36647776</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Willscher E, Paschold L, Gottschick C, Klee B, Bosurgi L, et al. . Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19. J Med Virol. (2023) 95:e28364. doi: 10.1002/jmv.28364</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28364</ArticleId><ArticleId IdType="pmc">PMC9878213</ArticleId><ArticleId IdType="pubmed">36458566</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V, Mahajan A, Spikes L, Krishnamachary B, Ram AK, Kumar A, et al. . Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol. (2023) 95:e28568. doi:&#xa0;10.1002/jmv.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28568</ArticleId><ArticleId IdType="pmc">PMC10048846</ArticleId><ArticleId IdType="pubmed">36756925</ArticleId></ArticleIdList></Reference><Reference><Citation>van Erp EA, van Kampen MR, van Kasteren PB, de Wit J. Viral infection of human natural killer cells. Viruses. (2019) 11:243. doi:&#xa0;10.3390/v11030243</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11030243</ArticleId><ArticleId IdType="pmc">PMC6466310</ArticleId><ArticleId IdType="pubmed">30870969</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Chiesa M, De Maria A, Muccio L, Bozzano F, Sivori S, Moretta L. Human NK cells and herpesviruses: mechanisms of recognition, response and adaptation. Front Microbiol. (2019) 10:2297. doi:&#xa0;10.3389/fmicb.2019.02297</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.02297</ArticleId><ArticleId IdType="pmc">PMC6788305</ArticleId><ArticleId IdType="pubmed">31636622</ArticleId></ArticleIdList></Reference><Reference><Citation>Adib-Conquy M, Scott-Algara D, Cavaillon JM, Souza-Fonseca-Guimaraes F. TLR-mediated activation of NK cells and their role in bacterial/viral immune responses in mammals. Immunol Cell Biol. (2014) 92:256&#x2013;62. doi: 10.1038/icb.2013.99</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2013.99</ArticleId><ArticleId IdType="pubmed">24366517</ArticleId></ArticleIdList></Reference><Reference><Citation>Mian MF, Lauzon NM, Andrews DW, Lichty BD, Ashkar AA. FimH can directly activate human and murine natural killer cells via TLR4. Mol Ther. (2010) 18:1379&#x2013;88. doi:&#xa0;10.1038/mt.2010.75</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.75</ArticleId><ArticleId IdType="pmc">PMC2911256</ArticleId><ArticleId IdType="pubmed">20442710</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneziani I, Alicata C, Pelosi A, Landolina N, Ricci B, D'Oria V, et al. . Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56(bright)CD16(-) subset. J Immunother Cancer. (2022) 10:e003385. doi:&#xa0;10.1136/jitc-2021-003385</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-003385</ArticleId><ArticleId IdType="pmc">PMC8804697</ArticleId><ArticleId IdType="pubmed">35091452</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneziani I, Infante P, Ferretti E, Melaiu O, Battistelli C, Lucarini V, et al. . Nutlin-3a enhances natural killer cell-mediated killing of neuroblastoma by restoring p53-dependent expression of ligands for NKG2D and DNAM-1 receptors. Cancer Immunol Res. (2021) 9:170&#x2013;83. doi:&#xa0;10.1158/2326-6066.CIR-20-0313</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-20-0313</ArticleId><ArticleId IdType="pubmed">33303573</ArticleId></ArticleIdList></Reference><Reference><Citation>Landolina N, Mariotti FR, Ingegnere T, Alicata C, Ricci B, Pelosi A, et al. . IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells. J Immunother Cancer. (2022) 10:e003858. doi:&#xa0;10.1136/jitc-2021-003858</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2021-003858</ArticleId><ArticleId IdType="pmc">PMC8928329</ArticleId><ArticleId IdType="pubmed">35292515</ArticleId></ArticleIdList></Reference><Reference><Citation>Mursalin MH, Coburn PS, Livingston E, Miller FC, Astley R, Flores-Mireles AL, et al. . Bacillus S-layer-mediated innate interactions during endophthalmitis. Front Immunol. (2020) 11:215. doi:&#xa0;10.3389/fimmu.2020.00215</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00215</ArticleId><ArticleId IdType="pmc">PMC7028758</ArticleId><ArticleId IdType="pubmed">32117322</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariotti FR, Petrini S, Ingegnere T, Tumino N, Besi F, Scordamaglia F, et al. . PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncoimmunology. (2019) 8:1557030. doi:&#xa0;10.1080/2162402X.2018.1557030</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2018.1557030</ArticleId><ArticleId IdType="pmc">PMC6350684</ArticleId><ArticleId IdType="pubmed">30723590</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte C. Possible link between SARS-coV-2 infection and parkinson's disease: the role of toll-like receptor 4. Int J Mol Sci. (2021) 22:7135. doi:&#xa0;10.3390/ijms22137135</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22137135</ArticleId><ArticleId IdType="pmc">PMC8269350</ArticleId><ArticleId IdType="pubmed">34281186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kathwate GH. In silico design and characterization of multi-epitopes vaccine for SARS-coV2 from its spike protein. Int J Pept Res Ther. (2022) 28:37. doi:&#xa0;10.1007/s10989-021-10348-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10989-021-10348-z</ArticleId><ArticleId IdType="pmc">PMC8722413</ArticleId><ArticleId IdType="pubmed">35002585</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggi E, Canonica GW, Moretta L. COVID-19: Unanswered questions on immune response and pathogenesis. J Allergy Clin Immunol. (2020) 146:18&#x2013;22. doi:&#xa0;10.1016/j.jaci.2020.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.001</ArticleId><ArticleId IdType="pmc">PMC7205667</ArticleId><ArticleId IdType="pubmed">32389590</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggi E, Azzarone BG, Canonica GW, Moretta L. What we know and still ignore on COVID-19 immune pathogenesis and a proposal based on the experience of allergic disorders. Allergy. (2022) 77:1114&#x2013;28. doi:&#xa0;10.1111/all.15112</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15112</ArticleId><ArticleId IdType="pmc">PMC8652765</ArticleId><ArticleId IdType="pubmed">34582050</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil BA, Elemam NM, Maghazachi AA. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. (2021) 19:976&#x2013;88. doi:&#xa0;10.1016/j.csbj.2021.01.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.01.034</ArticleId><ArticleId IdType="pmc">PMC7859556</ArticleId><ArticleId IdType="pubmed">33558827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortolotti D, Gentili V, Rizzo S, Rotola A, Rizzo R. SARS-coV-2 spike 1 protein controls natural killer cell activation via the HLA-E/NKG2A pathway. Cells. (2020) 9:1975. doi:&#xa0;10.3390/cells9091975</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9091975</ArticleId><ArticleId IdType="pmc">PMC7563485</ArticleId><ArticleId IdType="pubmed">32859121</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, et al. . Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. (2015) 67:3037&#x2013;46. doi:&#xa0;10.1002/art.39295</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39295</ArticleId><ArticleId IdType="pubmed">26251193</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. . Immunology of COVID-19: current state of the science. Immunity. (2020) 52:910&#x2013;41. doi:&#xa0;10.1016/j.immuni.2020.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. . Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. (2020) 130:4694&#x2013;703. doi:&#xa0;10.1172/JCI138554</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138554</ArticleId><ArticleId IdType="pmc">PMC7456250</ArticleId><ArticleId IdType="pubmed">32463803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MJ, Blish CA. Defining the role of natural killer cells in COVID-19. Nat Immunol. (2023) 24:1628&#x2013;38. doi:&#xa0;10.1038/s41590-023-01560-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01560-8</ArticleId><ArticleId IdType="pmc">PMC10538371</ArticleId><ArticleId IdType="pubmed">37460639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Byun JE, Yoon SR, Koohy H, Jung H, Choi I. SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity. Cell Immunol. (2022) 371:104454. doi:&#xa0;10.1016/j.cellimm.2021.104454</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2021.104454</ArticleId><ArticleId IdType="pmc">PMC8577527</ArticleId><ArticleId IdType="pubmed">34773897</ArticleId></ArticleIdList></Reference><Reference><Citation>Frolova EI, Palchevska O, Lukash T, Dominguez F, Britt W, Frolov I. Acquisition of furin cleavage site and further SARS-coV-2 evolution change the mechanisms of viral entry, infection spread, and cell signaling. J Virol. (2022) 96:e0075322. doi:&#xa0;10.1128/jvi.00753-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00753-22</ArticleId><ArticleId IdType="pmc">PMC9364789</ArticleId><ArticleId IdType="pubmed">35876526</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleem A, Akbar Samad AB, Vaqar S. Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19). Treasure Island (FL: StatPearls Publishing; (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">34033342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, et al. . TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. (2021) 22:829&#x2013;38. doi:&#xa0;10.1038/s41590-021-00937-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00937-x</ArticleId><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, et al. . NK cells are essential for effective BCG immunotherapy. Int J Cancer. (2001) 92:697&#x2013;702. doi:&#xa0;10.1002/(ISSN)1097-0215</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(ISSN)1097-0215</ArticleId><ArticleId IdType="pubmed">11340575</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteso G, Aguilo N, Julian E, Ashiru O, Ho MM, Martin C, et al. . Natural Killer anti-tumor activity can be achieved by in vitro incubation with heat-killed BCG. Front Immunol. (2021) 12:622995. doi:&#xa0;10.3389/fimmu.2021.622995</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.622995</ArticleId><ArticleId IdType="pmc">PMC7940681</ArticleId><ArticleId IdType="pubmed">33708215</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Kuang M, Li J, Zhu L, Jia Z, Guo X, et al. . SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. (2021) 31:818&#x2013;20. doi:&#xa0;10.1038/s41422-021-00495-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00495-9</ArticleId><ArticleId IdType="pmc">PMC7975240</ArticleId><ArticleId IdType="pubmed">33742149</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker I, Salaiza N, Aguirre M, Delgado J, Carrillo-Carrasco N, Kobeh LG, et al. . Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol. (2003) 130:65&#x2013;74. doi:&#xa0;10.1016/S0166-6851(03)00160-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-6851(03)00160-9</ArticleId><ArticleId IdType="pubmed">12946842</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza-Fonseca-Guimaraes F, Parlato M, Fitting C, Cavaillon JM, Adib-Conquy M. NK cell tolerance to TLR agonists mediated by regulatory T cells after polymicrobial sepsis. J Immunol. (2012) 188:5850&#x2013;8. doi:&#xa0;10.4049/jimmunol.1103616</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1103616</ArticleId><ArticleId IdType="pubmed">22566566</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connor GM, Hart OM, Gardiner CM. Putting the natural killer cell in its place. Immunology. (2006) 117:1&#x2013;10. doi:&#xa0;10.1111/j.1365-2567.2005.02256.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2005.02256.x</ArticleId><ArticleId IdType="pmc">PMC1782192</ArticleId><ArticleId IdType="pubmed">16423035</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantini C, Calzetti F, Perbellini O, Cassatella MA. On the co-purification of 6-sulfo LacNAc(+) dendritic cells (slanDC) with NK cells enriched from human blood. Immunobiology. (2009) 214:828&#x2013;34. doi:&#xa0;10.1016/j.imbio.2009.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2009.06.017</ArticleId><ArticleId IdType="pubmed">19589615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, et al. . Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol. (2006) 18:1115&#x2013;26. doi:&#xa0;10.1093/intimm/dxl046</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxl046</ArticleId><ArticleId IdType="pubmed">16728430</ArticleId></ArticleIdList></Reference><Reference><Citation>Millard AL, Spirig R, Mueller NJ, Seebach JD, Rieben R. Inhibition of direct and indirect TLR-mediated activation of human NK cells by low molecular weight dextran sulfate. Mol Immunol. (2010) 47:2349&#x2013;58. doi:&#xa0;10.1016/j.molimm.2010.05.284</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2010.05.284</ArticleId><ArticleId IdType="pubmed">20541808</ArticleId></ArticleIdList></Reference><Reference><Citation>Esin S, Counoupas C, Aulicino A, Brancatisano FL, Maisetta G, Bottai D, et al. . Interaction of Mycobacterium tuberculosis cell wall components with the human natural killer cell receptors NKp44 and Toll-like receptor 2. Scand J Immunol. (2013) 77:460&#x2013;9. doi:&#xa0;10.1111/sji.12052</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12052</ArticleId><ArticleId IdType="pubmed">23578092</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez J, Huang X, Yang Y. Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PloS Pathog. (2010) 6:e1000811. doi:&#xa0;10.1371/journal.ppat.1000811</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000811</ArticleId><ArticleId IdType="pmc">PMC2837413</ArticleId><ArticleId IdType="pubmed">20300608</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboudounya MM, Heads RJ. COVID-19 and toll-like receptor 4 (TLR4): SARS-coV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediators Inflammation. (2021) 2021:8874339. doi:&#xa0;10.1155/2021/8874339</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8874339</ArticleId><ArticleId IdType="pmc">PMC7811571</ArticleId><ArticleId IdType="pubmed">33505220</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandao SCS, Ramos JOX, Dompieri LT, Godoi E, Figueiredo JL, Sarinho ESC, et al. . Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? Cytokine Growth Factor Rev. (2021) 58:102&#x2013;10. doi:&#xa0;10.1016/j.cytogfr.2020.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.09.002</ArticleId><ArticleId IdType="pmc">PMC7505161</ArticleId><ArticleId IdType="pubmed">32988728</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Huda S, Sinha Babu SP. Toll-like receptor polymorphism in host immune response to infectious diseases: A review. Scand J Immunol. (2019) 90:e12771. doi:&#xa0;10.1111/sji.12771</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12771</ArticleId><ArticleId IdType="pubmed">31054156</ArticleId></ArticleIdList></Reference><Reference><Citation>Halajian EA, LeBlanc EV, Gee K, Colpitts CC. Activation of TLR4 by viral glycoproteins: A double-edged sword? Front Microbiol. (2022) 13:1007081. doi:&#xa0;10.3389/fmicb.2022.1007081</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.1007081</ArticleId><ArticleId IdType="pmc">PMC9557975</ArticleId><ArticleId IdType="pubmed">36246240</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Shafiei MS, Longoria C, Schoggins JW, Savani RC, Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-kappaB pathway. Elife. (2021) 10:e68563. doi:&#xa0;10.7554/eLife.68563</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.68563</ArticleId><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Pan S, Chen H, Yan S, Liu Y. Effect of TLR-4 gene polymorphisms on sepsis susceptibility in neonates: a systematic review and meta-analysis. biomark Med. (2022) 16:1005&#x2013;17. doi:&#xa0;10.2217/bmm-2022-0390</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2022-0390</ArticleId><ArticleId IdType="pubmed">36052709</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis. (2005) 5:156&#x2013;64. doi:&#xa0;10.1016/S1473-3099(05)70023-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(05)70023-2</ArticleId><ArticleId IdType="pubmed">15766650</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M, Rowntree LC, Hensen L, Chua BY, van de Sandt CE, Habel JR, et al. . Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep Med. (2021) 2:100208. doi:&#xa0;10.1016/j.xcrm.2021.100208</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100208</ArticleId><ArticleId IdType="pmc">PMC7862905</ArticleId><ArticleId IdType="pubmed">33564749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, Lynn MA, Mekonnen ZA, Yeow AEL, et al. . Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. (2022) 20:26. doi:&#xa0;10.1186/s12916-021-02228-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Claus M, Pieris N, Urlaub D, Brode P, Schaaf B, Durak D, et al. . Early expansion of activated adaptive but also exhausted NK cells during acute severe SARS-CoV-2 infection. Front Cell Infect Microbiol. (2023) 13:1266790. doi:&#xa0;10.3389/fcimb.2023.1266790</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2023.1266790</ArticleId><ArticleId IdType="pmc">PMC10499356</ArticleId><ArticleId IdType="pubmed">37712059</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>